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Abstract 
Introduction: The objective of this paper was to investigate the clinical features and pulmonary CT imaging features of COVID-19 patients 
with diabetes mellitus. 
Material and methods: From January 16, 2020 to March 28, 2020, among the 568 cases of COVID-19 patients diagnosed in Xiaogan Central 
Hospital, 64 cases of COVID-19 patients with diabetes were selected as the diabetic group, and 64 cases of COVID-19 patients with age 
and gender matching without diabetes were selected as the non-diabetic group, and their clinical data and pulmonary CT characteristics 
were retrospectively analysed.
Results: Compared with the non-diabetic group, the proportion of patients in the diabetic group with chronic underlying disease was 
higher, and they were in more a serious condition at admission. Inflammation index and characteristics of glycolipid metabolism results 
showed that COVID-19 patients with diabetes mellitus were more likely to have elevated inflammatory markers and hypercoagulability, 
accompanied by hypoproteinaemia and glucose and lipid metabolism disorders. Treatment and clinic outcome results showed that the 
time of nucleic acid turning negative in the diabetic group was significantly longer than that in the non-diabetic group. Radiological data 
showed that COVID-19 combined with diabetes prolonged the time of detoxification in patients.
Conclusion: COVID-19 patients with diabetes mellitus and chronic hypertension are associated with increased inflammatory markers 
and disorders of glucose and lipid metabolism. These patients tend to develop serious diseases, especially the rapid progression of CT 
lesions in the lungs of patients with a wide range of involvement, and prolonged absorption and detoxification time. (Endokrynol Pol 
2020; 71 (5): 367–375)
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Introduction
Coronaviruses are enveloped RNA viruses that are 
widely distributed in humans, other mammals, and 
birds, and which cause respiratory, intestinal, liver, 
and neurological diseases [1–2]. At present, six kinds 
of coronaviruses are known to cause human diseases 
[3]. In view of the high prevalence and wide distribu-
tion of coronaviruses, the huge genetic diversity, and 
frequent recombination of their genomes, as well as 
the increasing human-animal interface activities that 
induce frequent cross-species infections and occasional 
spillovers, new coronaviruses may appear periodically 
in human beings [4–5]. In December 2019, the outbreak 
of severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) was first reported in Wuhan, China, 
which had a huge impact on China and the world. The 
disease caused by SARS-CoV-2 was named as corona-
virus disease 2019 (COVID-19) [6]. In clinical practice, 
we have observed many severe or critically COVID-19 
patients with typical clinical manifestations of shock, 
including cold extremities and weak peripheral pulse. 
Even in the absence of obvious hypotension, many 
patients present with severe metabolic acidosis, sug-
gesting the possibility of microcirculatory dysfunction 
[7]. Furthermore, in addition to severe lung injury, some 
patients also have impaired liver and kidney functions 
[8], which suggests that COVID-19 may be associated 
with chronic underlying diseases.
As a representative of chronic basic diseases, diabe-
tes is a disease involving multiple metabolic disorders, 
characterised by high blood glucose concentration and 
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sputum, throat swabs, lower respiratory tract secretions, and other 
specimens were positive; 3 — diabetes was diagnosed according 
to the 1999 World Health Organisation (WHO) diagnostic criteria 
for diabetes [12]. This study was approved by the ethics commit-
tee of Xiaogan Central Hospital (ethics no.: XGLY2020-03-29) and 
conformed to the declaration of Helsinki.
Detection methods
After admission, fasting venous blood was collected in the morn-
ing and sent to the laboratory for blood routine examination and 
biochemical examination; the operation was carried out according 
to our laboratory instructions.
CT image collection
Two experienced physicians were employed to review the films, 
and they conducted quantitative accounting according to the dis-
tribution, location, size, morphology, edge, density, and pulmonary 
manifestations of the lesions.
Statistical analysis
Classification variables were expressed as frequency and per-
centage, continuous variables were expressed as average, and 
quantitative data of non-normal distribution were calculated 
by quartile. Chi-square test and Fisher exact test were used in 
the two groups of data, and t test or Mann-Whitney U test were 
used to analyse continuous variables. SPSS21.0 software was 
used for all statistical analysis. P < 0.05 was considered statisti-
cally significant.
Results
From January 16, 2020 to March 28, 2020, among the 568 
cases of COVID-19 (data not shown) patients diagnosed 
in Xiaogan Central Hospital, 64 cases of COVID-19 
patients with diabetes were selected as the diabetic 
group (hereinafter referred to as C-DM), and 64 cases 
of COVID-19 patients with age and gender matching 
without diabetes were selected as the non-diabetic 
group (hereinafter referred to as Non-C-DM) to study 
the clinical characteristics of patients with COVID-19 
combined with diabetes mellitus – 128 cases in total. 
Clinical characteristics of C-DM and Non-C-DM cases 
were summarised in Table 1. In detail, among the 128 
COVID-19 patients, the median age was 58 years [IQR 
(50-70)]; there were 74 males (57.81%) and 54 females 
(42.19%). The most common symptoms were fever 
(85.16%) and cough (71.09%); followed by dyspnoea 
(34.38%), fatigue (31.25%), and expectoration (25.78%); 
meanwhile diarrhoea (7.03%), myalgia (5.47%), diz-
ziness (2.34%), sore throat (2.34%), nausea (1.56%), 
and conjunctival congestion (0.78%) were relatively 
rare. The vast majority of patients had a clear contact 
history, including Wuhan tourism history (23.44%), 
Wuhan residential history (10.16%), and contact his-
tory with confirmed patients (21.88%); the proportion 
of patients with non-clear contact history was 44.53%. 
Hypertension (39.06%) was the most common chronic 
disease, followed by cardiovascular disease (8.59%) and 
cerebrovascular disease (2.34%).
inhibition of glucose oxidation, resulting in increased 
lipid metabolism, which in turn causes in hyperlipidae-
mia, hyperinsulinaemia, hypercoagulable symptoms, 
and other clinical symptoms [9]. At the same time, 
studies have shown that 71.4% of non-survivors of 
COVID-19 met the significant disseminated intravas-
cular coagulation grade (≥ 5, meeting the standards of 
the International Society on Thrombosis and Haemo-
stasis) and showed a significant correlation between 
abnormal coagulation results and poor prognosis at 
the later stage of COVID-19 disease [10]. An association 
between COVID-19 and diabetes has been suggested, 
but there is currently very limited research on the as-
sociation between COVID-19 and diabetes. Therefore, 
the focus of this present study was to explore the cor-
relation between COVID-19 and diabetes mellitus in 
terms of clinical features and pulmonary CT features. In 
addition, the clinical indexes, inflammatory indexes, 
glucose and lipid metabolism, and detoxification time of 
patients with COVID-19 combined with diabetes were 
studied. This article aims to make up for the limitations 
of the study of COVID-19 patients with diabetes, and 
at the same time provide a certain theoretical basis 




The patients’ epidemiological data, medical history, contact history, 
symptoms and signs, laboratory examination, complications, clini-
cal outcomes, CT imaging data, and treatment plan were extracted 
from electronic medical records. The date of onset of the disease was 
the date of the first symptom. The team analysed all the data, and 
it was double checked by two doctors. Nucleic acid detection was 
carried out by Xiaogan Central Hospital. At the time of admission, 
throat swab specimens were obtained from the patient’s upper 
respiratory tract and stored in a virus transport medium. Total RNA 
was extracted within two hours using the RNA separation kit of 
respiratory tract samples. Suspected cases were selected according 
to the diagnostic criteria for COVID-19 pneumonia [11]: 
1. Epidemiological history: 
 — travel or residence history in Wuhan or other areas with 
continuous transmission of local cases within 14 days before 
the onset of the COVID-19 disease; 
 — contact with patients with fever or respiratory symptoms from 
Wuhan or other areas where local cases continued to spread 
within 14 days before the onset of the COVID-19 disease; 
 — clusters of COVID-19 disease or epidemiological association 
with COVID-19 infection. 
2. Clinical manifestations: 
 — fever; 
 — with the above-mentioned imaging characteristics of pneu-
monia; 
 — normal or decreased total number of white blood cells in the 
early stage of COVID-19 disease, or reduced lymphocyte 
count. Suspected cases could be diagnosed if any one of them 
had an epidemiological history and conformed to any two 
of the clinical manifestations. 
Inclusion criteria for patients: 1 — suspected cases of COVID-19 
pneumonia; 2 — COVID-19 nucleic acid RT-PCR detection of 
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Table 1. Clinical characteristics of patients with diabetes (C-DM) and without diabetes (Non-C-DM)




(n = 64) p value
Age (years) 
Median (IQR) 52 (43–63) 52 (42–62) 58 (50–70) 0.004
Age groups (years) 
n (%)
≤ 39 107 (18.84) 101 (20.04) 6 (9.38) 0.040 
40–49 119 (20.95) 111 (22.02) 8 (12.5) 0.078 
50–59 158 (27.82) 137 (0.27) 21 (32.81) 0.344 
60–69 80 (14.08) 67 (13.29) 13 (20.31) 0.128 
≥ 70 104 (18.31) 88 (17.46) 16 (25.00) 0.142 
Gender  
n (%)
Male 309 (54.40) 272 (53.97) 37 (57.81) 0.561 
Female 259 (45.60) 232 (46.03) 27 (42.19) 0.561 
BMI [kg/m2]
≤ 18.5 21 (3.70) 19 (3.77) 2 (3.13) 1.000 
18.5 < BMI ≤ 24 288 (50.70) 265 (52.58) 23 (35.94) 0.012 
24 < BMI ≤ 28 193 (33.98) 167 (33.13) 26 (40.63) 0.233 
28 < BMI ≤ 32 52 (9.15) 42 (8.33) 10 (15.63) 0.057 
> 32 8 (1.41) 7 (1.39) 1 (1.56) 1.000 
Exposure history 
n (%)
History of residence in Wuhan 60 (10.56) 56 (11.11) 4 (6.25) 0.329 
Wuhan tourism history 126 (22.18) 115 (22.82) 11 (17.19) 0.307 
Contact history with confirmed patients 139 (24.47) 122 (24.21) 17 (26.56) 0.680 
Denied a clear contact history 243 (42.78) 211 (41.87) 32 (50.00) 0.215 
Comorbidities 
n (%)
Smoking 34 (5.99) 28 (5.56) 6 (9.38) 0.225 
Hypertension 139 (24.47) 107 (21.23) 32 (50.00) 0.000 
Cardiovascular disease 31 (5.46) 23 (4.56) 8 (12.50) 0.008 
Cerebrovascular disease 14 (2.46) 11 (2.18) 3 (4.69) 0.430 
Chronic pulmonary disease 23 (4.05) 20 (3.97) 3 (4.69) 1.000 
Chronic kidney diseases 4 (0.70) 3 (0.60) 1 (1.56) 0.938 
Chronic liver disease 22 (3.87) 22 (4.37) 0 (0) N/A
Rheumatic immune diseases 6 (1.06) 6 (1.19) 0 (0) N/A
Malignancies 17 (2.99) 12 (2.38) 5 (7.81) 0.016 
Clinical symptoms 
n (%)
Fever 507 (89.26) 453 (89.88) 54 (84.38) 0.180 
Cough 392 (69.01) 339 (67.26) 53 (82.81) 0.011 
Expectoration 144 (25.35) 124 (24.60) 20 (31.25) 0.250 
Dyspnoea 202 (35.56) 175 (34.72) 27 (42.19) 0.240 
Conjunctival congestion 1 (0.18) 0 (0) 1 (1.56) N/A
Pharyngalgia 30 (5.28) 27 (5.36) 3 (4.69) 1.000 
Dizziness 8 (1.41) 7 (1.39) 1 (1.56) 1.000 











Analysis report of COVID-19 patients with diabetes mellitus Yimin Yan et al.
As shown in Table 1, compared with the Non-C-DM 
group, the number of patients with chronic underly-
ing diseases complicated with hypertension in the 
C-DM group increased significantly (50.00% vs. 28.13%, 
p < 0.05). Cough symptoms were more common in the 
C-DM group (82.81% vs. 59.38%, p < 0.05). In addition, 
patients in the C-DM group were more likely to have 
decreased oxygen saturation and tachyarrhythmia at 
admission, in which oxygen saturation ≤ 93% (32.81% 
vs. 9.38%, p < 0.05) and heart rate > 100 bpm (25.00% 
vs. 10.94%, p < 0.05), indicating that patients in the 
C-DM group were in more a serious condition at ad-
mission.
Inflammation index and characteristics of glyco-
lipid metabolism of C-DM and Non-C-DM cases are 
summarised in Table 2. In particular, in comparison 
Table 2. Laboratory test of patients with diabetes (C-DM) and without diabetes (Non-C-DM)
Normal 
range





(n = 64) p value
Blood routine
White blood cell count [× 109/L] 3.5–9.5 5.07 (3.76–6.74) 4.64 (3.40–5.97) 5.65 (4.44–7.37) 0.006
Red blood cell count [× 1012/L] 3.92–5.61 4.39 (3.97–4.76) 4.33 (3.83–4.71) 4.47 (3.99–4.77) 0.563
Haemoglobin 115–150 137 (118–148) 138.00 (118.00–152.00) 135.50 (117.75–146.00) 0.335
Neutrophil [× 109/L] 1.5–6.3 3.45 (2.43–4.94) 3.08 (2.03–4.10) 4.15 (2.75–5.86) 0.003
Lymphocyte [× 109/L] 1.1–3.2 0.95 (0.70–1.38) 0.98 (0.73–1.42) 0.93 (0.64–1.32) 0.255
Platelets [× 109/L] 125–350 166 (124–222) 153.00 (120.00–207.00) 187 (130.75–267.75) 0.053
Blood coagulation
Active partial thrombin time (APTT) 23–45 31.00 (28.20–33.70) 31.85 (29.25–34.10) 30.50 (27.75–33.45) 0.140
PT 9–14 12.70 (11.90–13.70) 13.00 (12.23–13.78) 12.60 (11.75–13.65) 0.259
D-dimer (SDD) 0–1 0.30 (0.25–0.48) 0.28 (0.23–0.36) 0.34 (0.26–0.62) 0.007
TP 65–85 67.20 (63.70–72.63) 66.90 (63.70–72.45) 67.75 (63.73–72.73) 0.864
ALB 40–55 38.00 (35.18–40.73) 38.95(37.13–41.15) 36.80(34.83–39.63) 0.007
ALT 7–40 20.00 (13.00–33.25) 19.00 (12.75–34.25) 21.00 (14.00–32.25) 0.639
AST 13–35 24.00 (18.75–34.25) 24.50 (19.75–32.25) 24.00 (16.75–41.00) 0.888
Total bilirubin 0–23 12.05 (9.48–16.35) 12.50 (9.50–15.98) 11.95 (9.18–16.38) 0.884
Urea nitrogen 2.6–7.5 4.55 (3.30–5.83) 4.60 (3.50–5.60) 4.40 (3.10–6.45) 0.691
Creatinine 41–73 70.35 (60.15–85.25) 71.80 (62.98–86.78) 67.40 (56.03–84.18) 0.168
eGFR 94.74 (81.58–109.55) 93.55 (79.69–105.75) 102.58 (84.49–115.63) 0.076
LDH 120–250 245.50 (196.75–324.25) 226.50 (194.75–280.25) 271.50 (210.50–347.0) 0.019
ALP 40–150 69.00 (59.00–85.00) 69.00 (60.00–84.25) 67.00 (57.75–87.25) 0.924
FPG 3.89–6.11 6.19 (5.50–9.26) 5.58 (5.19–6.00) 8.85 (6.51–11.16) 0.000
TC 2.9–5.17 3.58 (2.93–4,18) 3.53 (2.93–4.13) 3.62 (2.95–4.25) 0.708
TG 0.23–1.7 1.33 (1.00–1.86) 1.11 (0.94–1.60) 1.54 (1.12–2.29) 0.000
Table 1. Clinical characteristics of patients with diabetes (C-DM) and without diabetes (Non-C-DM)




(n = 64) p value
Fatigue 185 (32.57) 164 (32.54) 21 (32.81) 0.965 
Nausea or vomiting 14 (2.46) 12 (2.38) 2 (3.13) 1.000 
Diarrhoea 28 (4.93) 24 (4.76) 4 (6.25) 0.832 
Temperature ≥ 37.3ºC 147 (25.88) 130 (25.79) 17 (26.56) 0.895 
SpO2 ≤ 93% 90 (15.85) 69 (13.69) 21 (32.81) 0.000 
HR > 100 89 (15.67) 73 (14.48) 16 (25.0) 0.029 
IQR — interquartile range; BMI — body mass index; Sp02 — oxygen saturation; HR — heart rate
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to the Non-C-DM group, C-DM group white blood 
cells [5.65 IQR (4.44–7.37) vs. 4.64 (3.40–5.97)], PCT 
[0.19 IQR (0.14–0.29) vs. 0.14 (0.11–0.28)], CRP (24.43 
IQR (6.47–68.05) vs. 15.90 (3.27–35.19)], ESR [55.00 
IQR (38.50–80.00) vs. 29.00 (21.50–60.00)], SDD [0.34 
IQR (0.26–0.62) vs. 0.28 (0.23–0.36)], FPG [8.85 IQR 
(6.51–11.16) vs. 5.58 (5.19–6.00)], and TG [3.62 IQR 
(2.95–4.25) vs. 3.53 (2.93–4.13)] increased, and albu-
min [36.80 IQR (34.83–39.63) vs. 38.95 (37.13–41.15)] 
decreased. These results suggested that COVID-19 
patients with diabetes mellitus are more likely to have 
elevated inflammatory markers and hypercoagulability, 
accompanied by hypoproteinaemia and glucose and 
lipid metabolism disorders.
Treatment and clinic outcome of C-DM and 
Non-C-DM cases are summarised in Table 3. In detail, 
compared with the Non-C-DM group, the propor-
tion of C-DM-group patients with respiratory failure 
(37.50% vs. 7.81%), requiring oxygen therapy (48.44% 
vs. 31.25%), and a non-invasive ventilator (17.19% 
vs. 3.13%) were significantly higher. Meanwhile, the 
C-DM group critical illness rate (28.13% vs. 3.13%) and 
the mortality rate (15.63% vs. 3.13%) were also signifi-
cantly higher than those in the Non-C-DM group. The 
median length of stay for all patients was 20 days, IQR 
(14–25). The length of stay in the C-DM group [22 IQR 
(16–27) vs. 17 (13–23)] was also relatively long, and the 
time of nucleic acid turning negative in the C-DM group 
was significantly greater than that in Non-C-DM group 
[18 IQR (15–22) vs. 23 (18–30)].
Radiological data of C-DM and Non-C-DM cases 
are summarised in Table 4. Specifically, according 
to the distribution characteristics and the range of 
involvement of COVID-19 lung CT, we counted the 
imaging characteristics of lung CT in the first week of 
admission. Among all the patients, the proportion of 
lesions involving both lungs was 79.69%, the propor-
tion of lesion distribution simultaneously involving 
peripheral and central areas was 50.78%, the propor-
tion of lesion size of > 3 cm was 78.91%, the propor-
tion of three or more lesions was 77.34%, and the 
proportion of lesion edge blur was 83.59%. In terms of 
lung CT lesion involvement location, compared with 
the Non-C-DM group (54.69% vs. 28.13%), the pro-
portion of peripheral and central involvement was 
higher the C-DM group (62.50% vs. 39.06%). In terms 
of lung CT lesion morphology, the Non-C-DM group 
was mostly affected by plaque (57.81% vs. 25.00%), 
while the lung lobes of C-DM group were often af-
fected (32.81% vs. 12.50%). More importantly, we cal-
culated the proportion of pulmonary CT progression 
at the first week and found that the C-DM group had 
significantly higher progession than the Non-C-DM 
group (92.19% vs. 60.94%, p < 0.001), while the time 
of pulmonary CT absorption was significantly greater 
in the C-DM group than in the non-diabetic group 
[26 IQR (16–34) vs. 19 (15–23)], p < 0.05 (Fig. 1). This 
proved our hypothesis that COVID-19 combined 
with diabetes might prolong the time of detoxifica-
tion in patients.
Table 2. Laboratory test of patients with diabetes (C-DM) and without diabetes (Non-C-DM)
Normal 
range





(n = 64) p value
Four items of chest pain
CKMB 0–4 2.48 (1.70–3.70) 2.20 (1.74–3.11) 2.60 (1.66–3.85) 0.414
BNP 0–125 227.00 (93.50–740.75) 247.00 (158.50–652.50) 191.50 (54.75–820.50) 0.296
cTnI 0.04–0.5 0.06 (0.03–0.08) 0.06 (0.04–0.09) 0.06 (0.03–0.08) 0.670
Infection-related indicators
PCT 0–0.5 0.17 (0.12–0.29) 0.14 (0.11–0.28) 0.19 (0.14–0.29) 0.096
CRP 0–3 19.61 (4.61–45.40) 15.90 (3.27–35.19) 24.43 (6.47–68.05) 0.029
ESR 0–20 39.50 (25.00–74.75) 29.00 (21.50–60.00) 55.00 (38.50–80.00) 0.045
Blood gas analysis
pH 7.35–7.45 7.43 (7.40–7.47) 7.43 (7.42–7.47) 7.44 (7.40–7.46) 0.557
PO2 83–108 80.15 (67.15–99.75) 84.40 (68.18–105.00) 74.75 (66.10–90.45) 0.793
PCO2 35–45 38.05 (32.55–41.73) 39.25 (36.03–42.45) 36.30 (30.80–40.75) 0.166
LAC 0.5–1.6 1.55 (1.10–2.00) 1.20 (0.09–1.68) 1.80 (1.30–2.90) 0.112
APTT — active partial thrombin time; PT — prothrombin time; TP — total protein; ALB — albumin propagated; ALT — alanine aminotransferase; AST — glutamates 
transaminase; eGFR — estimated glomerular filtration rate; LDH — lactate dehydrogenase; ALP — alkaline phosphatase; FPG — fasting plasma glucose;  
TC — total cholesterol; TG — triglyceride; CKMB — creatinase myocardial band; BNP — N-terminal brain natriuretic peptide precursor; cTnI — cardiac troponin;  
PCT — procalcitonin; CRP — C-reactive protein; ESR — Erythrocyte sedimentation rate; PO2 — oxygen partial pressure; PCO2 — partial pressure of carbon dioxide 
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Table 4. Radiological data of patients with diabetes (C-DM) and without diabetes (Non-C-DM)





(n = 64) p value
Lesion distribution
Left lung 8 (6.25) 7 (10.94) 1 (1.56) 0.068
Right lung 8 (6.25) 4 (6.25) 4 (6.25) 1.000
Double lung 102 (79.69) 49 (76.56) 53 (82.81) 0.380
Lesion location
Periphery 53 (41.41) 35 (54.69) 18 (28.13) 0.002
Periphery and centre 65 (50.78) 25 (39.06) 40 (62.50) 0.008
Lesion size [cm]
< 1 7 (5.47) 6 (9.38) 1 (1.56) 0.120
1~3 10 (7.81) 7 (10.94) 3 (4.69) 0.323
> 3 101 (78.91) 47 (73.44) 54 (81.38) 0.129
Lesion form
Patch 53 (41.41) 37 (57.81) 16 (25.00) 0.000
Lung segment 36 (28.13) 15 (23.44) 21 (32.81) 0.238
Lobe 29 (22.66) 8 (12.50) 21 (32.81) 0.006
Number of lesions
1 13 (10.16) 8 (12.50) 5 (7.81) 0.380
2 6 (4.69) 4 (6.25) 2 (3.13) 0.676
3 or more 99 (77.34) 48 (75.00) 51 (79.69) 0.526
Lesion margin
Clear 10 (7.81) 6 (9.38) 4 (6.25) 0.742
Vague 107 (83.59) 53 (82.81) 54 (81.38) 0.811
Lesion density
Ground glass 48 (37.50) 24 (37.50) 24 (37.50) 1.000
Substantiality 3 (2.34) 2 (3.13) 1 (1.56) 1.000




lymphadenopathy 0 0 0 N/A
Pneumothorax 0 0 0 N/A
Pleural effusion 8 (6.25) 4 (6.25) 4 (6.25) 1.000
Table 3. Treatment and clinical outcome of patients with diabetes (C-DM) and without diabetes (Non-C-DM)





(n = 64) p value
Oxygen n (%) 51 (39.84) 20 (31.25) 31 (48.44) 0.047
Non-invasive ventilator n (%) 13 (10.16) 2 (3.13) 11 (17.19) 0.019
Invasive ventilator n (%) 7 (5.47) 1 (1.56) 6 (9.38) 0.120
Complications  
n (%)
Respiratory failure 29 (22.66) 5 (7.81) 24 (37.50) 0.000
Heart failure 5 (3.91) 2 (3.13) 3 (4.69) 1.000
Septic shock 3 (2.34) 1 (1.56) 2 (3.13) 1.000
Clinical classification  
n (%)
Ordinary 80 (62.50) 52 (81.25) 28 (43.75) 0.000
Heavy 28 (21.88) 10 (15.63) 18 (28.13) 0.087
Critical type 20 (15.63) 2 (3.13) 18 (28.13) 0.000
Clinical outcome 
n (%)
Discharge 116 (90.63) 62 (96.88) 54 (84.38) 0.015
Death 12 (9.38) 2 (3.13) 10 (15.63) 0.034
Length of stay 20 (14–25) 17 (13–23) 22 (16–27) 0.029
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Coronaviruses are mostly round or oval in shape. They 
are named as coronaviruses because of their crown like 
appearance under an electron microscope. They can 
be divided into four genera: a, b, g, and d. COVID-19 
belongs to the b genus, with a diameter of 60–140 nm. 
Coronaviruses are mainly caused by binding with re-
ceptors in patients [13]. Lu et al. found that the receptor 
binding domain (RBD) of COVID-19 was similar to that 
of SARS CoV, through the construction of a homologous 
structure model. Hoffmann et al. proved that the recep-
tor of SARS CoV — angiotensin converting enzyme 2 
(ACE2) was also the cellular receptor of COVID-19, and 
it needed the participation of cytoprotease TMPRSS2 to 
complete the invasion [14, 15]. The COVID-19 mainly 
destroyed alveoli and deep bronchial epithelial cells, 
and its pathological features were mainly inflammatory 
infiltration. These pathological features are consistent 
with our statistical laboratory examination results, clini-
cal features, and CT imaging features.
According to the general situation of patients, we 
could observe that patients with COVID-19 compli-
cated with diabetes mellitus were more likely to have 
unstable vital signs, decreased oxygen saturation, rapid 
heart rate, etc. The laboratory test results showed that 
patients with COVID-19 complicated with diabetes 
mellitus were more likely to have inflammatory reac-
tions and hypercoagulable blood, and most of them 
were in severe condition at the time of admission. 
Previous studies also suggested that after COVID-19 
virus invasion of patients, the results of laboratory 
examination were mostly showed the decrease of 
peripheral lymphocytes and the passive activation of 
the immune system [16]. This was consistent with the 
statistical results in this present study. SARS-related 
studies have shown that blood glucose fluctuations 
play a positive role in promoting the generation 
of inflammatory storms and the poor prognosis of 
clinical outcomes [17]. Patients with diabetes mellitus 
complicated with COVID-19 can be hyperglycaemic 
due to improper diet, irregular use of hypoglycaemic 
Table 4. Radiological data of patients with diabetes (C-DM) and without diabetes (Non-C-DM)





(n = 64) p value
CT progress in the first week 98 (76.56) 39 (60.94) 59 (92.19) 0.000
CT absorption time 21 (16–29) 19 (15–23) 26 (16–34) 0.001
CT — computed tomography; N/A — not available
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drugs, and glucocorticoid drugs and other factors 
that affect blood sugar. Hyperglycaemia can further 
reduce lymphocytes, thereby causing overactivation 
of the immune system, while excessive activation and 
improper activation of the epidemic free system can 
cause inflammatory storm, which is often the reason 
for severe clinical symptoms [18]. Some studies also 
suggest that blood glucose can be increased after CO-
VID-19 virus invasion, and high blood glucose level 
is a high risk factor for disease progression. People 
with diabetes are more likely to be infected with CO-
VID-19 virus than people without diabetes because of 
their immune deficiency. When the virus invades, it 
mainly acts on the complement system. Complement 
immunity is one of the main mechanisms of humoral 
immunity. The complement system activates and me-
diates the production of antibodies at the time of the 
virus invading the body. However, in diabetic patients 
with immunodeficiency, the response to complement 
activation is decreased, and glycosylation can affect 
the expression of receptors in the complement activa-
tion system, resulting in diabetic patients being more 
susceptible to infection, and they are prone to change 
from mild patients to severe patients, with a higher 
mortality rate [19]. This was also consistent with the 
clinical outcome of this study that patients with CO-
VID-19 complicated with diabetes mellitus were more 
likely to develop respiratory failure and have a higher 
mortality rate than those without diabetes mellitus.
Compared with Non-C-DM, C-DM patients pre-
sented more lung segment and lobe infections on CT 
imaging. The area around the lesion was blurred and 
the boundaries were unclear. Lesions were found in 
the centre and around the lobes of both lungs, with 
a wide range, indicating severe lesions in C-DM pa-
tients. Studies found that COVID-19 mainly destroyed 
alveoli and deep bronchial epithelial cells, and its 
pathological features were mainly inflammatory 
infiltration. Under electron microscopy, tracheal epi-
thelial cells were swollen, local cilia disappeared, and 
diffuse alveolar destruction was observed. COVID-19 
caused exudation of high protein fluid, formation 
of a clear membrane, obvious monocyte infiltration, 
bronchiole were filled with cell debris, and there 
was apparent alveolar collapse with haemorrhage 
[20, 21]. The pathological characteristics were similar 
to those caused by SARS and Mars coronavirus, but 
the degree of fibrosis and consolidation was weaker 
than that caused by SARS, which was consistent with 
the characteristics of our CT imaging statistics in this 
study. Most of the CT imaging of COVID-19 patients 
are cumulative double lung, with lesions distributed 
in and around the centre of both lungs, and the lesion 
range is more than 3 cm.
According to the early autopsy results, the deep 
airway of the deceased patient was blocked by a large 
number of sputum plugs, which was consistent with 
the clinical manifestations [22]. Early studies con-
firmed that respiratory failure and circulatory failure 
were the main causes of death in COVID-19 patients 
[23]. The statistical results of this study showed that 
the proportion of C-DM patients complicated with 
respiratory failure during hospitalisation was higher 
than that of Non-C-DM and was statistically signifi-
cant. In addition, it could also be found that C-DM 
patients had more severe CT imaging manifestations 
and a wide range of lesions, consistent with the clini-
cal outcome. 
Conclusion
To sum up, we reported 128 confirmed patients with 
COVID-19 infection and explored the effect of diabetes 
on COVID-19 patients based on clinical indicators and 
CT imaging features. We have provided a theoretical 
basis and clinical guidance for the treatment of patients 
with COVID-19 complicated with diabetes mellitus.
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